Over the last twenty years there has been an increase in the prevalence and incidence of obesity and type 2 diabetes mellitus (T2DM), in the United States and in many countries around the world. More than one-third of US adults are obese and 29.1 million people in the United States are currently diagnosed with T2DM. Although weight loss is achievable and has been shown to be a successful mechanism of glycemic control, most are not able to maintain their weight loss. While several reasons have been proposed for the high rates of weight regain, there is substantial evidence that a biological drive to restore the elevated body weight prevents the long-term success of behavioral weight loss. Thus, therapeutic options that target both weight loss and glycemic control are attractive options for these patients and newer classes of drugs continue to be needed
|Effective start/end date||5/1/17 → 4/30/18|
- Endocrine Fellows Foundation (DID#22593)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.